Skip to content

The effectiveness of a pulsed radiofrequency treatment on radicular neuropathic pain.

The effectiveness of PRF-DRG treatment on radicular neuropathic pain.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON20488
Enrollment
46
Registered
2012-12-20
Start date
2013-02-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The intervention which will be studied is Pulsed radiofrequency treatment (PRF) on the dorsal root ganglion (DRG) by patients with radicular neuropathic patients. PRF uses radiofrequency current in sh
the “silent” phase (480 ms) of PRF allows time for heat elimination, generally keeping the target tissue below 42° C for 120 seconds. During the PRF treatment lidocaine will be injected. The control

Sponsors

Medisch Spectrum Twente (MST)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subject should have lumbar or sacral radicular neuropathic pain in dermatome L4, L5 or S1 where the pain is limited for 1 dermatome for at least 3 month. The subject should have a pain reduction of minimum 50% with a VAS score from 0 to 10 after a diagnostic block.

Exclusion criteria

Exclusion criteria: 1. Subject has sensory deficits at the QST site resulting from such medical conditions such as diabetes, alcoholic neuropathy, AIDS neuropathy, severe thyroid, liver or kidney diseases; 2. Former PRF or RF treatment of the same nerve root; 3. Subject has scar tissue, infection or acute injury at the QST site; 4. Language barriers and other problems impairing the reliable completion of questionnaires; 5. Subject is pregnant; 6. Subject has a pacemaker; 7. Subject has a major psychiatric disease or dementia; 8. History of back surgery; 9. Other chronic pain (such as fibromyalgia); 10. Anticoagulation in form of vitamin K antagonists which should not be stopped; 11. Skin diseases (such as herpes zoster, burns etc.); 12. Allergion for contrast or lidocaine.

Design outcomes

Primary

MeasureTime frame
Electrical quantitative sensory testing values before and after treatment.

Secondary

MeasureTime frame
1. VAS score; 2. Symptoms of pain (pain detect); 3. Medication use; 4. RAND-36 questionnaire; 5. HADS score.

Contacts

Public ContactInger Heerts

Haaksbergerstraat 55, poli 30

I.Heerts@mst.nl+31 (0)6 31751035

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)